Dr Jeremy Henson is presenting at the International Association for the Study of Pain (IASP) 2021 virtual world congress on pain (9-11 June and 16-18 June)
Abstract Title: Can improved mucosal absorption allow a THC/CBD oro-buccal spray to achieve clinical efficacy in chronic pain?
Dr Jermey discusses the results of a completed clinical study at RNSH investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers.
The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.
Presenting an update on current research is important for those physicians who are currently prescribing medicinal cannabis for the patients where traditional therapies have failed. The level of current evidence on medicinal cannabis efficacy is low to moderate, and further research is needed for the safety of patients.